Biotech remains a high-variance clinic. $RNAC pops 17% on a strategic licensing deal, showing how fast hope can pump a micro-cap. On the other side of the tape, $AIM craters 23% after dropping an at-the-market dilution offering directly on retail's head.
In 2,153 historical gap-down setups like $AIM, the bleeding rarely stops at the open, closing red 56% of the time. Don't catch falling knives in the dilution zone.
Then close the laptop and journal the day.